On Monday, Edwards Lifesciences Corp (NYSE: EW) opened lower -1.45% from the last session, before settling in for the closing price of $65.49. Price fluctuations for EW have ranged from $58.93 to $96.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 10.28%. Company’s average yearly earnings per share was noted 6.06% at the time writing. With a float of $592.02 million, this company’s outstanding shares have now reached $601.10 million.
Let’s determine the extent of company efficiency that accounts for 19800 employees. In terms of profitability, gross margin is 76.84%, operating margin of 27.02%, and the pretax margin is 27.62%.
Edwards Lifesciences Corp (EW) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Edwards Lifesciences Corp is 1.72%, while institutional ownership is 86.18%. The most recent insider transaction that took place on Sep 11 ’24, was worth 333,826. In this transaction CVP,Strategy/Corp Development of this company sold 5,000 shares at a rate of $66.77, taking the stock ownership to the 46,936 shares. Before that another transaction happened on Aug 20 ’24, when Company’s CVP, TMTT sold 1,250 for $69.95, making the entire transaction worth $87,438. This insider now owns 29,333 shares in total.
Edwards Lifesciences Corp (EW) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 6.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.00% during the next five years compared to 15.35% growth over the previous five years of trading.
Edwards Lifesciences Corp (NYSE: EW) Trading Performance Indicators
Check out the current performance indicators for Edwards Lifesciences Corp (EW). In the past quarter, the stock posted a quick ratio of 2.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.48. Likewise, its price to free cash flow for the trailing twelve months is 67.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.43, a number that is poised to hit 0.67 in the next quarter and is forecasted to reach 2.68 in one year’s time.
Technical Analysis of Edwards Lifesciences Corp (EW)
Looking closely at Edwards Lifesciences Corp (NYSE: EW), its last 5-days average volume was 6.46 million, which is a jump from its year-to-date volume of 4.56 million. As of the previous 9 days, the stock’s Stochastic %D was 31.71%. Additionally, its Average True Range was 1.89.
During the past 100 days, Edwards Lifesciences Corp’s (EW) raw stochastic average was set at 15.45%, which indicates a significant increase from 10.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 14.11% in the past 14 days, which was lower than the 64.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $66.54, while its 200-day Moving Average is $81.04. However, in the short run, Edwards Lifesciences Corp’s stock first resistance to watch stands at $65.15. Second resistance stands at $65.76. The third major resistance level sits at $66.34. If the price goes on to break the first support level at $63.97, it is likely to go to the next support level at $63.39. Now, if the price goes above the second support level, the third support stands at $62.78.
Edwards Lifesciences Corp (NYSE: EW) Key Stats
There are currently 602,600K shares outstanding in the company with a market cap of 38.88 billion. Presently, the company’s annual sales total 6,005 M according to its annual income of 1,402 M. Last quarter, the company’s sales amounted to 1,386 M and its income totaled 366,300 K.
